Trial site
Dermatologikum Hamburg Gmbh
Hamburg, 20354, GermanyNot linked to an institution yet
- 14running trials
- 7closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 28 trials
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed7 trials
- Active, not recruiting6 trials
- Recruiting5 trials
- Not yet recruiting3 trials
- Lead sponsor
- Sanofi3 trials
- Hoffmann-La Roche2 trials
- Takeda2 trials
- AbbVie1 trial
- Almirall S.A.1 trial
- and 12 more
Running trials
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
2026-525673-39-00· Phase 2· Apollo Therapeutics Limited· Source
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371· Phase 3· Nektar Therapeutics· Source
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813· Phase 2· Apollo Therapeutics Ltd· Source
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
NCT07223697· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
2024-519795-11-00· Phase 2· Apogee Therapeutics Inc.· Source
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· Phase 2· Inmagene LLC· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· Phase 3· Takeda· Source
Active, not recruiting
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948· Phase 2· Apogee Therapeutics, Inc.· Source
Active, not recruiting
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Plaque Psoriasis Involving Special Areas
2023-505122-34-00· Phase 3· Janssen - Cilag International· Source
Active, not recruiting
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
NCT06095102· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· Phase 2/3· Sanofi· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error